CORAL SPRINGS, Fla., Dec. 29, 2017 (GLOBE NEWSWIRE) -- Nutra Pharma Corporation (OTC:NPHC), a biotechnology
company marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, and which is also
developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain,
announced today that the Company's Chief Executive Officer, Rik J Deitsch, has published a Shareholder Letter on the Company's
website.
“This has been a very busy year at Nutra Pharma,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma
Corporation. “2017 provided some real challenges and opportunities for the Company. This has provided a strong platform for real
growth in 2018," he continued. "I wanted to take this opportunity to update our shareholders and the public on the accomplishments
of the year, the status of the Company and briefly outline our goals and expectations for the coming months,” he concluded.
The letter includes some of the following accomplishments made by the Company over the past year:
- We were featured in television news segments that ran nationally on NBC news from the NBC-Miami station and internationally
on the Spanish language show, Primero Impacto.
- We announced a collaboration with the International Security Group to investigate the use of our technology as a counter
measure against nerve agents.
- We announced a collaboration with the University Of Maryland Bioprocess Scale-Up Facility (BSF) to optimize
manufacturing processes for the production of RPI-78M for the planned upcoming clinical trials in Pediatric Multiple
Sclerosis.
- We launched Luxury Feet, a new version and packaging of our OTC pain drug, Nyloxin, specifically marketed for the
treatment and prevention of pain and discomfort that women experience from wearing high heels.
- We announced that the textbook, Multimodal Management of Canine Osteoarthritis, Second Edition, includes
references to Nutra Pharma's development of cobra venom-based products for treating pain in dogs; directly supporting Pet
Pain-Away.
The Shareholder Letter is available on the Company's website at: http://www.nutrapharma.com/Dec2017_shareholder_letter.pdf
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of
pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases,
including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the
Company markets drug products for sale for the treatment of pain under the brands: Nyloxin® and Pet Pain-Away™. For
additional information about Nutra Pharma, visit:
http://www.NutraPharma.com or
http://www.nyloxin.com
http://www.petpainaway.com
SEC Disclaimer
This press release contains forward-looking statements. The words or phrases "would be," "will allow,"
"intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar
expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in
Nutra Pharma's ("the Company") business plan. The publication of this Shareholder Letter should not be construed as an indication
in any way whatsoever of the future value of the Company’s common stock or its financial value. The Company's filings may be
accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should
not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless
otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any
forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such
statement.
Contact:
Nutra Pharma Corp.
Nina Goldstein
877-895-5647
IR@nutrapharma.com
